Biotech Values

[RNsidersbuying]

SIGA 1.40 / NLNK 24.02 - Two backdoor ebola plays both mentioned in recent Forbes article linked below? Anyone else notice the ebola death count has been rising recently on a daily basis to maybe 50+.

http://www.forbes.com/sites/scottgottlieb/2014/08/18/as-the-ebola-outbreak-expands-these-experimental-drugs-could-see-action/

About 1,000 doses of the vaccine, licensed to NewLink Genetics, a company in Ames, Iowa, may be tested in first responders, including healthcare providers, according to reports. Charles Link, the chief executive, said NewLink could manufacture tens of thousands of doses over the next couple of months.

SIGA (NASDAQ:SIGA) is an anti-infective company headquartered in New York is working closely with federal agencies to develop a range of compounds that target diseases that could be used as bioweapons, such as smallpox. The company has one compound that it is developing to target filo-viruses such as Ebola.